Belinostat exerts antitumor cytotoxicity through the ubiquitin‐proteasome pathway in lung squamous cell carcinoma
Sign Up to like & getrecommendations! Published in 2017 at "Molecular Oncology"
DOI: 10.1002/1878-0261.12064
Abstract: There have been advances in personalized therapy directed by molecular profiles in lung adenocarcinoma, but not in lung squamous cell carcinoma (SCC). The lack of actionable driver oncogenes in SCC has restricted the use of… read more here.
Keywords: cell carcinoma; squamous cell; belinostat; cytotoxicity ... See more keywords
Reversal of platinum drug resistance by the histone deacetylase inhibitor belinostat.
Sign Up to like & getrecommendations! Published in 2017 at "Lung cancer"
DOI: 10.1016/j.lungcan.2016.11.019
Abstract: OBJECTIVES To investigate and elucidate the mechanism for the potentiation of cisplatin anticancer activity by belinostat in platinum (Pt)-resistant lung cancer cells. MATERIALS AND METHODS Combination of cisplatin and belinostat was investigated in two pairs… read more here.
Keywords: resistance; cisplatin; lung cancer; belinostat ... See more keywords
Phase I trial of belinostat with cisplatin and etoposide in advanced solid tumors, with a focus on neuroendocrine and small cell cancers of the lung
Sign Up to like & getrecommendations! Published in 2018 at "Anti-Cancer Drugs"
DOI: 10.1097/cad.0000000000000596
Abstract: The standard-of-care for advanced small cell lung cancer (SCLC) is chemotherapy with cisplatin+etoposide (C+E). Most patients have chemosensitive disease at the outset, but disease frequently relapses and limits survival. Efforts to improve therapeutic outcomes in… read more here.
Keywords: infusion; small cell; cisplatin etoposide; belinostat ... See more keywords